An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy

Value in Health

Volumn 11, Issue 3, 2008, Pages 354-364

  Annemans, Lieven ^a,b   Demarteau, Nadia ^b,h   Hu, Shanlian ^c   Lee, Tae Jin ^d   Morad, Zaher ^e   Supaporn, Thanom ^f   Yang, Wu Chang ^g   Palmer, Andrew J ^b  

^a GHENT UNIVERSITY   (Belgium)

^b IQVIA   (United States)

^c FUDAN UNIVERSITY   (China)

^d Hallym University   (South Korea)

^e HOSPITAL KUALA LUMPUR   (Malaysia)

^f Phramongkutklao Army Hospital   (Thailand)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h Unit of IMS Health ^*  (Belgium)

Author keywords

Amlodipine; Cost effectiveness; Hypertension; Irbesartan; Nephropathy; Type 2 diabetes

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; IRBESARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASIA; CHINA; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIABETIC NEPHROPATHY; DIALYSIS; DRUG COST; EARLY INTERVENTION; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MICROALBUMINURIA; MONTE CARLO METHOD; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; SENSITIVITY ANALYSIS; SOUTH KOREA; TAIWAN; THAILAND;

EID: 44049106521     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00250.x     Document Type: Article

References (44)

1. H King RE Aubert WH Herman Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
2. Y Dong W Gao H Nan Prevalence of type 2 diabetes in urban and rural Chinese populations in Qingdao, China Diabet Med 22 2005 1427 1433
3. S Wild G Roglic A Green Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053
4. BE Mustaffa Diabetes epidemic in Malaysia Med J Malaysia 59 2004 295 296
5. H Wang L Zhang J Lv Prevention of the progression of chronic kidney disease: practice in China Kidney Int 94 Suppl. 2005 S63 S67
6. G Lee End-stage renal disease in the Asian-Pacific region Semin Nephrol 23 2003 107 114
7. YN Lim TO Lim 12th Report of the Malaysian Dialysis and Transplant Registry 2005 National Renal Registry Malaysia
8. US Renal Data System USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2005 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD Available from: http://www.usrds.org/atlas.htm [Accessed March 2006].
9. JP Vora HA Ibrahim GL Bakris Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management J Hum Hypertens 14 2000 667 685
10. EJ Lewis JB Lewis Treatment of diabetic nephropathy with angiotensin II receptor antagonist Clin Exp Nephrol 7 2003 1 8
11. JL Gross MJ de Azevedo SP Silveiro Diabetic nephropathy: diagnosis, prevention, and treatment Diabetes Care 28 2005 164 176
12. H-H Parving H Lehnert J Brochner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
13. EJ Lewis LG Hunsicker WR Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
14. AJ Palmer DM Tucker WJ Valentine Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies Nephrol Dial Transplant 20 2005 1103 1109
15. AJ Palmer L Annemans S Roze An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting J Hum Hypertens 18 2004 733 738
16. AJ Palmer L Annemans S Roze Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension Dtsch Med Wochenschr 129 2004 13 18
17. AJ Palmer L Annemans S Roze An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings Nephrol Dial Transplant 18 2003 2059 2066
18. AJ Palmer L Annemans S Roze Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease Diabetes Care 27 2004 1897 1903
19. World Health Organization Life tables for 191 countries. World mortality in 2002 Available from: http://www3.who.int/whosis/life_tables/life_tables.cfm?path=evidence,life_tables&language=english [Accessed June 2005].
20. Ministry of the Interior Statistics Department (Taiwan, Republic of China). Abridged Life Tablein Taiwan Area 2003 Available from: http://sowf.moi.gov.tw/stat/english/elife/inface2003.htm [Accessed June 2005].
21. P Gaede P Vedel N Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
22. CD Stehouwer MA Gall JW Twisk Increased urinary albumin excretion, endothelial dysfunction, and chronic lowgrade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death Diabetes 51 2002 1157 1165
23. International Bank for Reconstruction and Development 2006 world development indicator, in March Available from: http://devdata.worldbank.org/wdi2006/contents/Tables4.htm [Accessed March 2007].
24. CIA The World Fact book Available from: http://www.umsl.edu/services/govdocs/wofact2006/rankorder/2004rank.html [Accessed March 2007].
25. MR Gold JE Siegel LB Russell MC Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
26. AH Briggs Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 2000 479 500
27. LS Hooi TO Lim A Goh Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals Malaysia Nephrology (Carlton) 10 2005 25 32
28. IG Cheah AP Soosai SL Wong Cost-Effectiveness NICU Study Group Cost-effectiveness analysis of Malaysian neonatal intensive care units J Perinatol 25 2005 47 53
29. CY Loo M Kandiah G Arumugam Cost efficiency and cost effectiveness of cataract surgery at the Malaysian Ministry of Health ophthalmic services Int Ophthalmol 25 2004 81 87
30. RF Pwu KA Chan Related cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan J Formos Med Assoc 101 2002 632 641
31. M Barbieri M Drummond R Willke Variability of cost-effectiveness estimates for pharmaceuticals in western Europe: lessons for inferring generalizability Value Health 8 2005 10 23
32. Taiwan Nephrology Society. 2003 statistics.
33. DP Walters W Gatling AC Houston Mortality in diabetic subjects: an eleven-year follow-up of a community-based population Diabet Med 11 1994 968 973
34. TO Lim YN Lim 11th Report of the Malaysian Dialysis and Transplant Registry 2004 National Renal Registry Malaysia
35. Department of Health. DOH statistical report (1993–1996 survey Taiwan).
36. PK Li BC Kwan CB Leung Prevalence of silent kidney disease in Hong Kong: the screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program Kidney Int 94 Suppl. 2005 S36 S40
37. Thailand Renal Replacement Therapy Registry Available from: http://www.nephrothai.org 2003 [Accessed February 2004].
38. Thailand Renal Transplantation Registry Available from: http://www.thai-transplant.org 2004 [Accessed February 2004].
39. JQ Qian WM Zhang XQ Xu Registry annual report of dialysis and transplant in China 1999 Chin J Nephrol 17 2001 77 78
40. YH Zhu SL Hu XL Chen The cost and disease economic burden analysis on hemodialysis and peritoneal dialysis Chin J Hosp Admin 19 2003 413 416
41. LP Jiang SL Hu SL Zheng Cost-effectiveness analysis of the different immunosuppression regimen against acute rejection response after renal transplantation J Wenzhou Med Coll 34 2004 417 419
42. Taiwan Bureau of National Health Insurance. 2004.
43. Veterans General Hospital Taichung 2000 statistics.
44. Drugs and Medical Supplies Information Center, Ministry of Public Health Available from: http://dmsic.moph.go.th/ [Accessed February 2004].